Drugs / BTM-3566
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07266285 | Dec 2025 → Feb 2027 expected | cancer | Bantam Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06792734 | Feb 2025 → Feb 2027 expected | B-cell non-Hodgkin lymphoma | Bantam Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Bantam Pharmaceuticals | Results Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B bantampharma.com ↗
In vitro and in vivo response of tumor cells to BTM-3566 is inversely correlated with the expression of the mitochondrial protein FAM210B. |
| 2025-04-25 | Bantam Pharmaceuticals | Results Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025 bantampharma.com ↗
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced solid tumor regression data from Bantam’s lead product candidate, BTM-3566. |
| 2025-03-06 | Bantam Pharmaceuticals | Regulatory Bantam Pharmaceutical Accelerates BTM-3566 Clinical Program Expanding Phase 1 Trial into Canada bantampharma.com ↗
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced it is proceeding with a Phase 1 clinical trial evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. |
| 2024-12-18 | Bantam Pharmaceuticals | Results Solid Tumor Data Presented at 36th EORTC Symposium on Molecular Targets & Cancer Therapeutics bantampharma.com ↗
BTM-3566 targets mitochondrial quality control pathways leading to cell growth arrest in sensitive solid tumor line of diverse origins. |
| 2024-07-30 | Bantam Pharmaceuticals | Results Bantam Data in Collaboration with MD Anderson Presented at 2024 AACR Conference bantampharma.com ↗
BTM-3566 has robust in vitro efficacy in DLBCL cell lines irrespective of genomic background and elicits complete tumor regression in multiple cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models of DLBCL. |
| 2023-09-06 | Bantam Pharmaceuticals | Results Bantam & Collaborators Published in Molecular Cancer Therapeutics, an AACR Journal bantampharma.com ↗
Both compounds induce rapid apoptosis across diverse DLBCL lines derived from activated B-cell, germinal center B-cell, and MYC-rearranged lymphomas. |
| 2022-04-08 | Bantam Pharmaceuticals | Results Bantam Pharma Featured in Nature BioPharma Dealmakers bantampharma.com ↗
In an expanded panel of high-risk human DLBCL PDX models BTM-3566 demonstrated a 100% response rate, and complete tumor regression in 6 of 9 PDX models. |
| 2021-12-13 | Bantam Pharmaceuticals | Results Data on Bantam Pharmaceutical’s Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual ASH Meeting bantampharma.com ↗
BTM-3566:novel small molecule with potent single agent activityin DLBCL |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTM-3566 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266285 ↗ |
| Known as | BTM-356 | “The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors.” NCT07266285 ↗ |
| Route | Oral | “Daily oral dosing (7 days on/7 days off)” NCT07266285 ↗ |